12:00 AM
Nov 12, 2012
 |  BC Week In Review  |  Company News  |  Deals

MorphoSys, Novartis deal

The partners added MorphoSys' Ylanthia and Slonomics technology for antibody optimization to a 2007 deal granting Novartis exclusive access to MorphoSys' HuCAL antibody technology. The companies will cross-license...

Read the full 119 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >